Avidity Biosciences Inc. to Participate in Upcoming Investor Conference

Avidity Biosciences Inc., a biotechnology company specializing in the development of novel antibody oligonucleotide conjugates therapeutics, has announced its participation in an upcoming investor conference. The company, which operates in the health care sector and is based in La Jolla, United States, aims to engage with investors and stakeholders to discuss its strategic initiatives and advancements in overcoming delivery barriers for oligonucleotides. These conjugates are designed to treat various serious diseases, highlighting Avidity’s commitment to innovation in the biotech field.

As of May 5, 2025, Avidity Biosciences Inc. is listed on the Nasdaq stock exchange with a close price of $26.26. The company’s market capitalization stands at approximately $3.94 billion, reflecting its significant presence in the biotechnology sector. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $56 on November 12, 2024, and a 52-week low of $21.51 on April 8, 2025.

The investor conference participation underscores Avidity’s proactive approach in maintaining transparency and fostering relationships with its investor community. This engagement is crucial as the company continues to navigate the competitive landscape of biotechnology and seeks to expand its impact in the health care sector.

For more detailed information about Avidity Biosciences Inc. and its offerings, stakeholders are encouraged to visit the company’s website at www.aviditybiosciences.com .